drugset / Trial / NCT04607655
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis
Timeline
- Start
- 2021-03
- Primary completion
- 2022-07
- Completion
- 2022-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selvigaltin | Small molecule | 10 mg | Oral |
| Subject | Selvigaltin | Small molecule | 100 mg | Oral |